Contribution of tumoral and host solute carriers to clinical drug response

详细信息	查看全文 | 推荐本文 |

• 作者：Jason A. Sprowl^a ; Torben S. Mikkelsen^b ; Hugh Giovinazzo^a ; ¹ ; Alex Sparreboom^a ; ^{alex.sparreboom@stjude.org}
• 关键词：Anticancer drugs ; Drug disposition ; Pharmacodynamics ; Solute carriers
• 刊名：Drug Resistance Updates
• 出版年：2012
• 期刊代码：14_13687646
• 类别：bio
• 出版时间：February-April, 2012
• 卷：15
• 期：1-2
• 页码：5-20
• 文件大小：910 K

摘要

Members of the solute carrier family of transporters are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues. Several of these solute carriers are known to be expressed in cancer cells or cancer cell lines, and decreased cellular uptake of drugs potentially contributes to the development of resistance. As result, the expression levels of these proteins in humans have important consequences for an individual's susceptibility to certain drug-induced side effects, interactions, and treatment efficacy. In this review article, we provide an update of this rapidly emerging field, with specific emphasis on the direct contribution of solute carriers to anticancer drug uptake in tumors, the role of these carriers in regulation of anticancer drug disposition, and recent advances in attempts to evaluate these proteins as therapeutic targets.